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Abstract: Everolimus (RAD001, Afinitor® Novartis) is the first oral inhibitor of mTOR (mammalian 
target of rapamycin) to reach the oncology clinic. Everolimus 10 mg daily achieves complete inhibi-
tion of its target at below the maximum tolerable dose for most patients. A phase III randomized 
placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal 
cancers and progressive disease on or within 6 months of the VEGFR tyrosine kinase inhibitors 
sunitinib and/or sorafenib. The primary endpoint of progression-free survival was increased from 
median 1.9 to 4.9 months (hazard ratio 0.33, P  0.001) and 25% were still progression-free after 
10 months of everolimus therapy. There was a delay in time to decline of performance status and 
trends to improvement in quality of life, disease-related symptoms, and overall survival despite 
crossover of the majority of patients assigned to placebo. In 2009, everolimus was approved in the 
US and Europe as the only validated option for this indication. Toxicities are usually mild to moderate 
and can be managed with dose reduction or interruption if necessary. Opportunistic infections and 
non-infectious pneumonitis are seen as a class effect. Management of common practical manage-
ment issues are discussed. Clinical trials are in progress to examine additional roles for everolimus 
in renal cancer, alone and in combination with other agents.
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Introduction
Kidney cancer, more specifically renal cell cancer (RCC), is a significant cause of 
premature death and has been resistant to drug therapy until the past 5 years. There 
will be a projected 4600 new cases and 1600 deaths from kidney cancer in Canada in 
2009,1 and 8 times that number in the US.2 About two-thirds of these events will occur 
in men, partly related to smoking incidence that increases risk substantially.3 There is 
no proven role for population screening or prevention. An average of 14.2 years of life 
are lost to each person dying of kidney cancer (based on British Columbia data).4
The extent of disease at the initiation of systemic therapy for advanced RCC 
is a major predictor of outcome, and patients can be divided into three prognostic 
groups – good, intermediate, or poor risk – using the Memorial Sloan-Kettering criteria5 
with or without the additional predictive power of the number of involved sites.6 The 
most common presentation of advanced kidney cancer is now during follow-up after 
nephrectomy: such patients are often asymptomatic and in better general health than 
in the past with low metastatic burden and less comorbidity. A further substantial fit 
group of patients will have metastases diagnosed on screening before nephrectomy. 
Improving survival figures are in part due to lead-time bias from earlier recognition and 
therapy of metastases with the advent of more options. For example the median survival Biologics: Targets & Therapy 2010:4 92
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of the interferon alfa randomized trial arms in two pivotal 
studies was 9 months in 1999,7 compared with 20 months in 
2008 allowing for crossover to a more active agent.8 Patients 
are therefore often candidates for multiple sequential lines 
of systemic therapy that are the focus of this review. Smaller 
cohorts of patients present with symptoms from metastases, 
paraneoplastic syndromes, or locally advanced tumors in the 
kidney, and may require a more palliative approach such as 
radiation as well as attempted systemic therapies.
There have been four eras of systemic therapy for 
advanced renal cancer: hormone therapy, chemotherapy, 
immunotherapy,9 and currently targeted therapy.10 One 
published randomized controlled trial has used a placebo 
control demonstrating that the natural history of RCC can 
sometimes be indolent, with 6.6% spontaneous partial 
remissions.11 Hormone therapy has been widely used as 
control therapy7 even recently.12 RCC is strikingly resistant 
to chemotherapy despite most new agents being tested. In the 
1980s, immunotherapy became the dominant drug therapy, 
based on occasional durable remissions in highly selected 
patients treated with high dose interleukin-2,13 and small 
survival gains with the more generally applicable agent 
interferon alfa.7,14 Interferon became the safe and common 
standard of care for metastatic RCC;5 however most patients 
did not benefit and toxicity was substantial, setting the stage 
for the present era of targeted drugs.9
The first major recent advance was the recognition that 
renal cell cancer (RCC) includes several diagnostic entities 
that differ at the molecular level. The most common type of 
RCC is clear cell (ccRCC), about 75% of kidney cancers.15 
Families with the rare von Hippel Lindau syndrome develop 
vascular tumors including ccRCC, and studies indentified 
underlying loss of a recessive tumor suppressor gene 
now known as the VHL gene. Subsequently it was shown 
that sporadic ccRCC has biallelic deletion, mutation, or 
methylation of the VHL gene, and this feature has a major 
role in the pathogenesis of the disease.16 Loss of the normal 
VHL gene product in ccRCC results in constitutional high 
expression of the hypoxia response gene HIF-1α (hypoxia-
inducible factor 1 alpha) and its many downstream products 
including angiogenic growth factors like vascular endothelial 
growth factor (VEGF). Recently introduced drugs that 
target the VEGF pathway include bevacizumab (Avastin®; 
Genentech) with or without interferon alfa, and especially the 
VEGFR TKIs (VEGF receptor small molecule tyrosine kinase 
inhibitors) sunitinib (Sutent®; Pfizer), sorafenib (Nexavar®; 
Bayer), and others in various stages of development. Of these 
agents, only sunitinib has resulted in unequivocally improved 
overall survival for good and intermediate risk patients 
compared to first-line interferon alfa,17 and is now approved 
and widely used for first-line therapy of advanced ccRCC. 
Sorafenib is the best documented agent for second-line 
therapy after interferon alfa.18 Therefore there are increasing 
numbers of good performance status patients in need of 
further active treatment of metastatic RCC after disease 
progression on or soon after sunitinib and/or sorafenib. 
Everolimus (RAD001, Afinitor®; Novartis) has emerged as 
the leader in that setting, and the first to receive approval in 
the USA (March 2009) and Europe (August 2009) for use 
after failure of VEGFR TKI therapy.19 Poor prognostic risk 
patients treated with the intravenous mTOR inhibitor tem-
sirolimus (CCI-779, Torisel® Wyeth) have improved overall 
survival,20 but represent a more palliative clinical situation 
than good-intermediate risk patients suitable for multiple 
lines of therapy.
Discovery and development  
of rapamycin and rapalogs
Rapamycin (sirolimus) is a macrolide antibiotic named 
for the remote Pacific island of Rapa Nui (formerly Easter 
Island), the origin of a soil sample obtained in 1965 
(Figure 1) which yielded a new streptomycete, Streptomyces 
hygroscopicus, from which rapamycin was later derived 
at Ayerst Research Labs in Montreal.21 This discovery 
deserves major recognition because extended investigations 
of rapamycin and its derivatives successively demonstrated 
a unique combination of antifungal, immunosuppressive,22 
antineoplastic,23 and even anti-aging properties.24 In 1999, 
Figure 1 A plaque commemorating the discovery of rapamycin (sirolimus) on Rapa 
Nui (Easter Island), near Rano Kau. The plaque is written in Brazilian Portuguese, and 
reads: In this location were obtained, in January 1965, soil samples that led to the 
discovery of rapamycin, a substance that inaugurated a new era for organ transplant 
patients. An homage from the Brazilian investigators, November 2000. Photo credit: 
Anypodetos, Wikipedia Commons.Biologics: Targets & Therapy 2010:4 93
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rapamycin was approved in the USA for immunosuppression 
after organ transplantation and marketed as Rapamune® 
(Wyeth-Ayerst). Its target is a highly conserved kinase known 
in mammals as mTOR (mammalian target of rapamycin). 
Rapamycin has no other target so the inhibition of mTOR is 
one of the most specific targeted drug actions known.
The original compound rapamycin was too insoluble 
and unstable for parenteral use as an antineoplastic agent.25 
Subsequently rapamycin ester analogs have been developed, 
known as rapamycins,25 or rapalogs.26 Current rapalogs include 
temsirolimus, everolimus (RAD001, Afinitor®), and agents 
still in development such as ridaforolimus (deforolimus, 
AP23473 Ariad®; Ariad Pharmaceuticals). These rapalogs 
have similar and highly selective action discussed below 
such that at least some overlap of clinical efficacy, toxicity, 
and predictors of benefit might be expected.
Mechanism of action of rapalogs
mTOR has a role in cell growth, proliferation, cell 
survival, and angiogenesis. Unravelling mTOR function 
is still incomplete but much progress has been made and a 
number of excellent reviews are available.23,25–30 Originally 
identified from rapamycin-resistant yeast strains, TOR and its 
homologues are highly conserved in evolution, and centrally 
located in molecular pathways involved in cell proliferative 
responses to external factors including insulin-like growth 
factors and availability of oxygen and nutrients. mTOR is a 
large single chain polypeptide with 2549 amino acids and at 
least 5 binding domains (Figure 2).
mTOR forms two different multi-protein complexes 
called mTORC1 and mTORC2. mTORC1 is formed with 
raptor (regulatory protein of mTOR) and mLST8, and 
upon activation via the upstream PI3K-Akt pathway, has 
Ser/Thr kinase activity for its main downstream targets 
S6K1 (ribosomal p70S6 kinase 1), and 4E-BP1 (4E binding 
protein 1) resulting in disinhibition of the eukaryotic 
initiation factor 4E (eIF4E) and translation of multiple cell 
cycle regulating proteins (Figure 3). Recently an additional 
component of mTORC1, PRAS40 (proline rich Akt substrate 
40 kDa), has been described that may allow Akt to directly 
inhibit TORC1 in energy-deprived conditions.23 mTORC1, but 
not mTORC2, is directly inhibited by rapamycin complexed 
to a cytophilin FKBP12 (originally identified as the binding 
protein for the immunosuppressive agent tacrolimus, FK-
506). Rapamycin binds with high affinity (Kd ∼0.3 nM) and 
specificity by binding into a hydrophobic cleft between mTOR 
and FKBP12.31
mTORC1 is located on the PI3K-Akt-mTOR-p70S6K 
pathway, upregulated in many malignancies, that increases 
transcription of protein RNAs including HIF-1 (hypoxia 
inducible factor 1). HIF-1 lies at the crossroads for agents 
that target the mTOR pathway and those that target the VEGF 
pathway discussed earlier, thereby providing the basis for 
consecutive or concurrent use of agents that target the two 
HEAT repeats FAT FRB Se/Thr Kinase NRG FATC
rapalog 
FKBP12
raptor  mLST8 
mTOR domains
Everolimus
Figure 2 mTORC1, mammalian target of rapamycin complex 1, consists of mTOR, raptor (regulatory protein of mTOR), and mLST8 (mammalian lethal with SEC 13).   
An additional component, PRAS40, has been omitted (see text). mTOR domains27 are shown in italics. The serine/threonine kinase catalytic activity is inhibited by the binding 
to FRB (FKBP12-rapamycin binding protein) of the rapalog-FKBP12 complex (rapamycin analogs complexed to the cytophilin FK-506 binding protein 12 kD).Biologics: Targets & Therapy 2010:4 94
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pathways. It should however be noted that the site of action 
for VEGF targeted agents is thought to be vascular endothelial 
cells, whereas mTOR inhibitors act directly on tumor cells, 
as well as support tissues such as vascular endothelium 
where there are differences from VEGFR inhibitors.32 The 
combined pathway actions of everolimus provide a rationale 
for radiosensitization especially observed against vascular 
endothelium.33 Strategies for overcoming resistance may 
be novel for targeted agents and different for the VEGF and 
mTOR pathways.34
The role of a second complex of mTOR, mTORC2, is 
becoming clearer and requires revision of the simplistic 
cascade referred to previously. Inhibition of mTOR disrupts 
S6K negative feedback on the insulin receptor substrate 
(IRS) precursor of the Akt pathway resulting in undesirable 
upregulation and a potential mechanism of resistance.35 
However in a minority of cell lines, prolonged rapamycin 
exposure also inhibits mTORC2 that is a key activator of 
Akt and therefore could mitigate or even block the Akt path-
way.28,29 The mechanism of rapamycin inhibition of mTORC2 
is not fully elucidated but could be by intracellular scaveng-
ing of mTOR. Another reason to block mTORC2 is that it 
appears to control the expression of HIF-2α that may be 
more important than HIF-1α in RCC.36 The complex pathway 
feedback loops are challenging for disease control but also 
provide numerous opportunities for the combination of evero-
limus with agents that block other targets,23 but whether these 
combinations will prove to have a higher therapeutic index 
than their consecutive use remains to be seen.
Clinical pharmacology
The approach to determining the standard dose of a 
chemotherapy agent in phase I trial is escalation to the 
maximum tolerated dose (MTD). However, targeted agents 
may fully block their target(s) below the MTD and this dose 
may be directly assessed especially where there is a single 
target as with mTOR inhibitors.37 Such an approach was 
used in the clinical development of temsirolimus and sub-
sequently with everolimus. The dose-dependant antitumor 
efficacy of everolimus was shown in a rat pancreatic 
tumor model to correlate with prolonged inactivation of 
ribosomal protein S6 kinase 1.38 This relationship was 
examined in detail in phase I human studies with similar 
effects also seen for the other mTOR downstream effector 
eukaryotic initiation factor p4E-BP1.39,40 Modelling sug-
gested that a daily schedule would exert a greater effect 
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Figure 3 Major mTOR pathways.
Notes: mTORC1 = mTOR complex 1, the major site of inhibition for everolimus, but also results in disruption of negative feedback loop via S6K; mTORC2 inhibition occurs in 
a minority of cell lines; * = tumor suppressor gene, may be inactivated in RCC; *PTEN = phosphatase and tensin homologue; *VHL = Von Hippel Lindau gene product; *REDD 
= regulated in development and DNA damage; IR = insulin receptor; IRS = insulin receptor substrate; PI3K = phosphoinositol 3 kinase; TSC = tuberous sclerosis complex; 
Rheb = Ras homologue enriched in brain; S6K = ribosomal p70S6 kinase; 4EBP = 4E binding protein; eIF4E = eukaryotic initiation factor 4E; HIF = hypoxia inducible factor; 
VEGF = vascular endothelial growth factor.Biologics: Targets & Therapy 2010:4 95
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than weekly administration.41 Everolimus 10 mg by mouth 
daily was recommended for phase II studies.42
At least five metabolites of everolimus are known, all 
with low mTOR inhibitory effect.43 Unlike temsirolimus, 
everolimus is not a prodrug of rapamycin. The majority of 
metabolite excretion is hepatic – biliary – fecal. The peak 
concentration is reduced by a high fat diet, but the AUC is 
not; the AUC is proportional to dose. The terminal half-life 
is approximately 30 hours.44
Efficacy of everolimus: phase II
A phase II study of everolimus 10 mg daily for ccRCC has 
been completed and fully published.45 Forty-one patients 
were enrolled and were generally good performance status 
and minimally treated: 17% had no prior systemic therapy, 
62% had one prior immunotherapy, and 22% had a VEGF 
inhibitor or other therapy. 37 were assessable for efficacy, 
with 14% objective partial remissions lasting 8 to 37 months 
and another 57% with stable disease for more than 6 months 
(the majority with at least minor tumor shrinkage). The safety 
analysis observed grade 1–2 anorexia, nausea, diarrhea, 
rash, and stomatitis in 10% of treated patients, grade 
1–3 pneumonitis in 49%, and a variety of laboratory changes. 
However only 13/39 patients required a dose reduction to 
5 mg, and no patient withdrew because of drug toxicity. These 
findings were confirmed in an additional cohort of patients 
previously treated with sunitinib or sorafenib,46 paving the 
way to the subsequent phase III study.
Second-line phase III study: 
RECORD-1; NCT00410124 
(clinicaltrials.gov)
RECORD-1 (REnal Cell cancer treatment 
with Oral RAD001 given Daily)
A pivotal trial of second-line everolimus for advanced clear 
cell RCC has been fully reported.47,48 All patients had pro-
gressive disease on (75%) or within 6 months (25%) after 
prior treatment with sunitinib, sorafenib, or both agents. 
Patient eligibility also required measurable disease, as well 
as adequate organ function and Karnofsky performance 
status (minimum KPS 70%, capable of self-care). The 
investigators used exemplary design and methodology, with 
central randomization, placebo control, independent blind 
radiologic review, and intent-to-treat analysis. It was powered 
to detect a 50% improvement in the primary endpoint of 
progression-free survival (PFS) allowing for two interim 
analyses. Patients were stratified by risk category,49 and by 
number of VEGFR TKIs (1 vs 2). All 410 enrolled patients 
received best supportive care; additionally two thirds of 
patients were randomly assigned to receive everolimus and 
one third received identically appearing placebo tablets. The 
patients, investigators, and independent assessment reviewers 
were all unaware of the random assignment. Everolimus 
10 mg was taken daily by mouth unless protocol-specified 
adverse events (AEs) required a delay and/or dose reduction 
to 5 mg daily. Over three-quarters of enrolled patients were 
KPS 90% to 100% despite being heavily pretreated – over 
half had received immunotherapy, chemotherapy, or radiation 
in addition to sunitinib and/or sorafenib. The trial was closed 
early after the second interim analysis (first efficacy analysis) 
showed that a pre-specified degree of benefit had been 
surpassed and the criterion for a positive study met. The risk 
for disease progression at study closure on the everolimus 
arm was reduced by 70% compared to placebo (Figure 4) 
with similar reduction on more mature analysis (hazard 
ratio [HR] 0.33, 95% confidence interval [CI] 0.25 to 0.43, 
P  0.001).48 All pre-specified and exploratory subgroups 
appeared to show improvement in the primary outcome of 
delayed progression resulting from disease stabilization and 
minor tumor shrinkage: 67% of everolimus vs 32% placebo-
treated patients had stable disease for at least 8 weeks. 
Updated median PFS was 4.9 vs 1.9 months and, more 
importantly, the probability of remaining progression-free 
for at least 10 months was 25% on everolimus vs 2% on 
placebo.48 However remissions as conventionally defined 
by RECIST criteria50 occurred in only 2% of patients on 
the active treatment arm, and overall survival was similar 
for patients receiving everolimus or placebo. There was no 
difference in the time to deterioration of global quality of 
life (QOL) in the initial report,47 but subsequent analyses of 
performance status and disease-related symptoms did suggest 
a benefit.48 The time to a decline in performance status was 
longer on everolimus than placebo (5.8 vs 3.8 months, HR 
0.66, P = 0.004). A summary of efficacy measures from the 
RECORD-1 trial is presented in Table 1.
Therefore although a robust biological effect was clearly 
demonstrated, the clinical utility of this effect is less obvious 
and interpretation is required. For example, it is possible 
that there were beneficial effects on QOL resulting from 
stability and minor remissions that were offset by adverse 
effects of everolimus, a balance that might be quite sensitive 
to the details of toxicity management. PFS benefit may be a 
predictor of overall survival impact for this disease,51,52 and 
a beneficial impact on survival might be obscured by the 
protocol requirement to permit crossover of placebo-treated Biologics: Targets & Therapy 2010:4 96
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patients to receive everolimus after investigator-assessed 
disease progression, justified by ethical and recruitment 
considerations;47 112/139 (81%) patients initially assigned to 
placebo did cross to everolimus and enjoyed a median PFS of 
5.1 months, ie, very similar duration to those initially assigned 
to the everolimus arm. In the absence of standardized ways 
to examine such possibilities, further analyses by post-hoc 
crossover censoring techniques must be regarded as hypoth-
esis generating but are consistent with an improvement in 
overall survival (Table 1).53,54
Safety and tolerability of everolimus
Everolimus has turned out to be relatively safe and well 
tolerated, considering that mTOR blockade might cause 
disruption of diverse molecular pathways or serious 
consequences of immunosuppression. In the pivotal phase 
III study,47 safety was evaluated every 2 weeks for 6 weeks 
and then monthly, using the US National Cancer Institute 
Criteria v3.0.55 Due to adverse events, 39% of patients 
required a dose reduction from everolimus 10 mg to 5 mg 
by mouth daily, with or without temporary interruption of 
therapy, compared to 15% on placebo; 13% discontinued 
active treatment because of toxicity compared with 2% on 
placebo, usually because of lung disorder or fatigue.47,48 The 
subjective toxicities that were seen at least 10% more often 
in patients assigned to everolimus compared to placebo 
were stomatitis or mucosal inflammation, rash, asthenia, 
diarrhea, and nausea, mostly grade 1 or 2. Anemia and 
fatigue were common in both study arms. The following 
events occurred to grade 3 or 4 significantly more often 
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Figure 4 Kaplan–Meier estimates of progression-free survival. Reprinted from The Lancet. 372:449–456. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced 
renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Copyright © 2008, with permission from Elsevier.
Table 1 Efficacy measures from RECORD-1 trial
Everolimus Placebo HR P
Progression-free survival47 4.9 months 1.9 months 0.33 0.001
Overall survival (OS)48 14.8 months 14.4 months 0.87 0.177
aOS (method 1)53 0.55 0.039
aOS (method 2)54 14.8 months 10.0 months 0.53 not stated
Time to PS decline48 5.8 months 3.8 months 0.66 0.004
KFSI-DRS score48 4.8 3.8 0.75 0.053
aCorrected for crossover after disease progression on placebo to everolimus.
Abbreviations: KFSI-DRS score, FACT-Kidney Symptom Index – Disease Related Symptoms; OS, overall survival; PS, performance status.Biologics: Targets & Therapy 2010:4 97
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in patients receiving everolimus than placebo: stomatitis, 
infections, pneumonitis, elevated cholesterol, hyperglycemia, 
lymphopenia, and hypophosphatemia. Four deaths were 
attributed to everolimus, one each due to pneumonitis, sepsis, 
candidiasis, and aspergillosis (Table 2).
A serious class toxicity for rapalogs including everolimus 
is drug-induced (non-infectious) pneumonitis,56 and this 
may be substantially more common than clinically appar-
ent. For example, a blinded retrospective review of a 
phase III trial of temsirolimus found that 29% of patients 
had radiologic pneumonitis, compared to 9% clinical 
pneumonitis with dyspnea or cough and only 1% discon-
tinued therapy.57 Likewise, a single institution subset of 
the RECORD-1 pivotal study of everolimus observed CT 
radiologic changes in 46% but only 7% clinical drug-induced 
pneumonitis.58 Only grade 3 or clinical pneumonitis requires 
drug interruption or discontinuation, others may be treated 
symptomatically and monitored for deterioration or resolu-
tion; grade 4 life-threatening pneumonitis was not seen. The 
average time to development of pneumonitis was 4 months 
and half were treated with steroids.48 A more detailed analysis 
and recommendations for pneumonitis management arising 
from this study is pending.47
Expanded access experience  
of everolimus
Following presentation of the early RECORD-1 study 
results,59 in July 2008 an expanded access program that 
made everolimus available to patients following therapy 
with sunitinib or sorafenib had enrolled 342 patients in 
22 countries as of April 2009,60 and is ongoing in some 
locations pending regulatory approval.61 Eligibility permitted 
non-measurable disease. The safety profile is similar to 
the phase III study with no new toxicities recognized. 
Seventeen percent discontinued due to AE, similar to the 
phase III experience. However, of the first 168 patients for 
whom data are available, 71% experienced at least one grade 
3 or 4 toxicity, suggesting that close monitoring and patient 
education are required to more clearly define the indications 
for dose reduction or interruption for evolving toxicity.
The question arises as to the use of everolimus following 
disease progression with new VEGFR tyrosine kinase 
inhibitors as these become available for study. The most 
recent additions to this drug family are axitinib (AG13736, 
Pfizer) and pazopanib (GW786034, GlaxoSmithKline), oral 
multikinase inhibitors with demonstrated activity in phase II 
studies and now in phase III trials. In phase II, pazopanib 
achieved a 35% objective response rate in patients who had 
not received prior VEGFR TKI therapy.62 Axitinib achieved 
a response rate of 23% in patients who had all received prior 
sorafenib.63 Such patients would appear to be eligible for 
inclusion in the expanded access study of everolimus,61 and the 
differential efficacy of everolimus after different VEGFR TKI 
sequences may become available in due course. In the mean-
time it is reasonable to use everolimus in this setting based on 
generally similar experience after sunitinib or sorafenib.
Although we do not yet have patient satisfaction data, 
it is likely that this treatment will be well received since it 
is very convenient as a daily oral pill, has proven efficacy 
in stabilizing the disease temporarily in the majority of 
patients, and is the only proven effective option after failure 
of VEGR TKIs. Significant toxicity is seen but, in most 
patients, is readily manageable with symptomatic care and 
dose modification or temporary interruption.
Practical management  
of safety issues
The integration of everolimus into clinical practice is at a 
preliminary stage. It appears that the safety profile of oral 
everolimus is similar to its analog temsirolimus, available 
since 2007 as a weekly intravenous treatment and for which 
practical management is well established.64–66 The principles 
are: safety monitoring, early detection of toxicities or disease 
progression, and action appropriate to a palliative therapy. 
Serious toxicity is to be minimized by early treatment 
interruption and restart at a reduced dose of everolimus 
5 mg/day if tolerated.
Patient selection
Approved patient selection is for tyrosine kinase refractory 
disease (progression on or immediately after), ambulatory 
performance status, adequate bone marrow and hepatic 
function, and clear cell predominant histology.
Table 2 Serious adverse events in RECORD-1 trial47,48
Everolimus Placebo
Treatment-related death 1% 0
Discontinued for AE 13% 2%
Dose reduction for AE 39% 15%
Clinical pneumonitis 14% 0
Infections 13% 2%
Stomatitis gr 3–4 3% 0
Lymphopenia gr 3–4 15% 5%
Hyperglycemia gr 3–4 12% 1%
High cholesterol gr 3–4 3% 0
Abbreviations: AE, adverse event; gr, grade55Biologics: Targets & Therapy 2010:4 98
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Table 3 Practical recommendations for everolimus therapy44
Pretreatment checklist
1.  Pretreatment suitability (see text ‘Patient-selection’).
2.  Medication list for CYP450 3A4 inhibitors or inducers (strong inhibitors should not be co-administered).66
3. Afinitor® counseling information eg, common adverse events, avoid live vaccines and grapefruit juice
4.  Provide patient with reporting instructions, eg, fever, respiratory symptoms
5.  Record baseline tumor/symptom evaluation, repeat every 8 weeks
6.  Lab at baseline and every 4 weeks (or more often if risk factors such as diabetes are present)
Lab = CBC and differential, phosphorus, LFT, creatinine, fasting glucose, cholesterol, triglycerides
7.  CXR at baseline and every 8 weeks or if cough/dyspnea develop
8.  CT chest if lung disease or lung metastases present: at baseline and as needed for re-evaluation
Duration until disease-progression, unacceptable toxicity despite dose reduction, or patient refusal
Dosage modification
Note: dose is not adjusted for body size (did not reduce interpatient variation for temsirolimus).67
Common situations
100%: everolimus 10 mg by mouth daily taken consistently at same time and with or without food
50%: 5 mg daily for grade 3–4 toxicities on full dose, after interruption until grade 2 or better
Special situations
On CYP450 3A4 inducer: cautious dose escalation if no grade 2 toxicity after 4 weeks at 10 mg
On CYP450 3A4 strong inhibitor: start at 5 mg daily, increase cautiously after 4 weeks if no grade 2 AE
Persistent or unacceptable grade 2 toxicities at 10 mg dose: 10 mg alternating with 5 mg
Moderate hepatic impairment (Child–Pugh class B): 5 mg daily
Renal impairment: no modification required
Management of specific problems
Neutropenic infections – as for chemotherapy-related febrile neutropenia
Lymphopenic infections – consider possible opportunistic infections such as Candida or Aspergillus
Non-infectious pneumonitis (by exclusion – no clinical or other evidence of infection)
–  grade 1–2, continue everolimus but monitor weekly until stable/improving
–  grade 3, hold therapy until improved; consider corticosteroid eg, prednisone 25–50 mg with rapid taper before resuming everolimus at lower dose
Hyperglycemia – home glucometer, diet modification/oral agents or insulin as required, maintain dose
Hypertriglyceridemia – diet modification
Hypercholesterolemia – diet modification; prevastatin if necessary (other statins are CYP450 substrates)66
Hypophosphatemia – oral phosphate replacement
Stomatitis, rash, diarrhea – symptomatic management
Diabetics: high risk of hyperglycemia grade 2+ (based on temsirolimus data).68
Abbreviations: AE, adverse events; CBC, complete blood count and differential; LFT, liver function tests; CXR, chest X-ray; CT, computerized tomography.
Where permitted, off-label use in non-clear cell RCC 
may be considered since temsirolimus has some evidence 
to support its use in that context.69 Everolimus is in phase II 
for patients with papillary renal cancers,70,71 and prior to 
nephrectomy for patients with metastases at diagnosis.72
Prediction of benefit of mTOR 
inhibitors
Much needed for targeted agents in general are biomarkers 
to predict patients who are more likely or very unlikely to 
benefit. A substantial study of 375 patients investigated 
the prognostic significance of mTOR pathway components 
in tumors obtained at nephrectomy, and observed adverse 
prognostic impact on disease-specific survival of pS6K, 
PTEN and Akt independent of stage.73 A small study further 
suggested that pS6K and possibly Akt were predictors of 
response to temsirolimus for advanced RCC.67,74 However an 
extension of the study20 of temsirolimus for poor prognosis 
advanced RCC did not find a correlation between PTEN and 
HIF-1α with outcome.75 Work on biomarkers to predict ben-
efit of everolimus is underway.76 Once treatment is initiated, it 
may be possible to assess pharmacokinetic effects on glucose 
metabolism in as little as a week by PET scanning.77
Ongoing clinical research
Everolimus has an established place as the preferred single 
agent for second-line treatment of ccRCC after sunitinib 
and/or sorafenib. Research is actively examining additional Biologics: Targets & Therapy 2010:4 99
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scenarios for its use. Many combinations of everolimus with 
other classes of targeted drugs or chemotherapy are being 
tested in phase I/II trials. The relevant combinations for 
ccRCC combine everolimus with another agent that targets 
the same PI3K/Akt/mTOR pathway at another level (vertical 
blockade), or a different pathway (horizontal blockade).78 
Vertical blockade with everolimus and imatinib was toxic, gave 
PFS similar to everolimus alone, and was not recommended 
for further development.79 Horizontal blockade combining 
everolimus with a VEGF pathway inhibitor is proceeding 
actively eg, sunitinib,80 sorafenib,81 or bevacizumab. Of these, 
the everolimus – bevacizumab combination is the only one 
where both drugs are tolerated at full dose,82 has promising 
activity,83 and has now reached randomized phase II testing 
compared to the established IFN-bevacizumab regimen in 
the first-line setting (RECORD-2 study).84 Agents that block 
mTOR complex 2 or the S6K feedback loop (Figure 3) would 
be of special interest.26
Now that multiple oral targeted agents are available and 
adequately well tolerated for chronic use, trials are starting 
to examine whether there might be a preferred sequence 
eg, for inhibition of the mTOR and VEGF pathways. The 
phase III RECORD-3 study85 will randomize patients to 
everolimus or sunitinib first-line, and cross-over to the other 
agent at disease progression.
Conclusions
Consequent to a large well performed phase III trial, everolimus 
has become the standard second-line agent after the approved 
first-line drugs sunitinib and/or sorafenib for patients with 
advanced clear cell renal cancer. The majority of patients with 
advanced disease are now diagnosed early at presentation or on 
surveillance after nephrectomy and remain in good performance 
status for an extended time and so are eligible for everolimus. 
Everolimus has been recently approved by the FDA in the USA, 
and by European Medicines Agency in Europe. Guidelines in 
developed countries for the treatment of RCC are reasonably 
concordant,86 and now include everolimus as the preferred 
treatment for VEGFR inhibitor resistant disease in the USA,87 
Europe,88 and Canada.89 Future randomized trials in the sec-
ond-line setting after VEGF pathway inhibitors will need to use 
everolimus as comparator in the control arm. The benefits of 
second-line everolimus are modest with temporary stablization 
the most common advantage over placebo. Everolimus drug 
combinations and/or use earlier in the disease may confer 
greater benefits. The impact on overall survival has become 
difficult to demonstrate because of crossover of patients to 
the alternate arm. Validated and agreed statistical methods are 
needed and appear feasible for the use of censoring techniques 
to determine survival benefit in a crossover setting.53,54
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